CompletedPhase 2NCT03038022

Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)

Studying Rare hypercholesterolemia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Madrigal Pharmaceuticals, Inc.
Principal Investigator
Rebecca Taub, MD
Madrigal Pharmaceuticals, Inc.
Intervention
MGL-3196 (resmetirom)(drug)
Enrollment
116 enrolled
Eligibility
18 years · All sexes
Timeline
2017 – 2018

Study locations (13)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03038022 on ClinicalTrials.gov

Other trials for Rare hypercholesterolemia

Additional recruiting or active studies for the same condition.

See all trials for Rare hypercholesterolemia →

← Back to all trials